Richard Branson backs $4bn float of genetics firm 23andMe The Virgin Group founder launched investment company VG Acquisition Corp last September 27 January 2021 • 8:07pm Sir Richard Branson’s “blank cheque” investment company is closing in on its first deal by masterminding the $4bn (£3bn) float of 23andMe, a genetics firm that aims to predict whether Covid sufferers will develop a severe case of the virus. VG Acquisition Corp, one of a new breed of special purpose acquisition companies known as SPACs, will be used to launch 23andMe’s stock market debut. The float is expected to be finalised in the coming weeks, deal insiders said.